Applied DNA Clinical Labs (ADCL), a subsidiary of Applied DNA Sciences, said this week that it has submitted a validation package to the New York State Department of Health (NYSDOH) to support the approval of a pharmacogenomics assay as a NYSDOH laboratory-developed test (LDT). If approved, the LDT test will be used by ADCL to power its population-scale PGx testing services. The company said its commercial strategy is centered on the direct-to-enterprise and self-insured health markets that do not require ADCL to seek third-party reimbursement or engage in individual patient billing.